Showing 6,166 results

Filters Content type: News, Editors' picks, About HIV Topic: HIV treatment

Treatment is recommended for all people living with HIV. It involves taking a combination of antiretroviral drugs. This stops the virus from replicating and allows the immune system to strengthen and fight infections.

Injectable & long-acting HIV treatment

Compassionate Use of Long-Acting Cabotegravir Plus Rilpivirine in HIV

Editor's pick
Infectious Disease Advisor
26 September 2022
New & experimental HIV treatments

Merck restarts islatravir HIV treatment studies, but abandons monthly PrEP

News
23 September 2022
The search for a cure

License to Kill: Latency HIV-CRISPR pinpoints how to blow latent HIV’s cover

Editor's pick
Fred Hutch
21 September 2022
New & experimental HIV treatments

Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection

Editor's pick
Merck press release
20 September 2022
Changing treatment

A Switch to B/F/TAF Keeps HIV Suppressed, Even With Mutation

Editor's pick
Medscape (requires free registration)
20 September 2022
HIV treatment in pregnancy

Better viral suppression with dolutegravir than other antiretrovirals in pregnancy, but not all guidelines recommend it

News
20 September 2022
Weight gain & lipodystrophy

Weight gain and HIV treatment A research briefing

About HIV
September 2022
Harm reduction

Can Substance Use Treatment Improve HIV Care?

Editor's pick
POZ
15 September 2022
Side effects

Go Slow Before Switching HIV Meds Due to Metabolic Effects

Editor's pick
Infectious Disease Special Edition
14 September 2022
The search for a cure

AIDS 2022 Highlights in Cure Research

Editor's pick
TheBodyPro
13 September 2022
Changing treatment

Inflammatory Biomarkers in HIV Support Safety of Switching to 2-Drug Antiretroviral Therapy

Editor's pick
Infectious Disease Advisor
8 September 2022
Resistance

HIV patients in Botswana get adequate treatment but not all of them – one group is slipping through the cracks

Editor's pick
The Conversation
6 September 2022
HIV treatment in pregnancy

Dolutegravir-based antiretroviral therapies for HIV-1 effective in pregnancy

Editor's pick
EurekAlert
1 September 2022
HIV treatment

Immune Responses to ART Vary by Regimen Among Individuals With Advanced HIV

Editor's pick
American Journal of Managed Care
31 August 2022
PrEP

HIV seroconversions on PrEP in Australian study are linked to low adherence

Editor's pick
i-Base
31 August 2022
TB epidemiology

Zambian patients on dolutegravir and recycled tenofovir regimens have high risk of TB even after switch

News
31 August 2022
Treatment interruptions

HIV Viral load at Diagnosis Predicts Time to Rebound After Treatment Interruption

Editor's pick
Infectious Disease Advisor
26 August 2022
New & experimental HIV treatments

European Commission approves first twice-yearly HIV medication

News
25 August 2022
HIV treatment

Best-in-class second-line HIV treatment rolls out in Zambia and Nigeria

Editor's pick
Clinton Health Access Initiative
25 August 2022
HIV treatment for children & young people

South Africa puts child-friendly ARV treatment on hold

Editor's pick
Health-e
24 August 2022
Bone & joint problems

Vitamin D and calcium supplements suggested to avert bone disease in people taking tenofovir-based ART and PrEP

News
24 August 2022
Injectable & long-acting HIV treatment

UNAIDS responds to EU approval of a long acting HIV treatment option: “To end AIDS, share technology.”

Editor's pick
UNAIDS
23 August 2022
Injectable & long-acting HIV treatment

Long-acting cabotegravir and rilpivirine may be feasible for people without viral suppression

News
23 August 2022
Pharmaceutical industry

Gilead bags first approval for twice-yearly HIV therapy

Editor's pick
Pharmaphorum
22 August 2022